Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway by González-Alvaro, I et al.
Inhibition of tumour necrosis factor and IL-17
production by leflunomide involves the JAK/STAT
pathway
I Gonza ´lez-Alvaro,
1 A M Ortiz,
1 C Domı ´nguez-Jime ´nez,
1 A Arago ´n-Bodi,
1
BD ı ´az Sa ´nchez,
1 FS a ´nchez-Madrid
2
c Additional supplementary
table 1 is published online only
at http://ard.bmj.com/content/
vol68/issue10
1Rheumatology, Hospital
Universitario de la Princesa.
Madrid, Spain;
2Immunology
Units, Hospital Universitario de
la Princesa. Madrid, Spain
Correspondence to:
Dr I Gonzalez-Alvaro,
Rheumatology Unit, Hospital
Universitario de la Princesa.
Madrid, Spain; isidoro.ga@ser.es
Accepted 3 October 2008
Published Online First
25 October 2008
ABSTRACT
Objective: To study the effects of different disease-
modifying antirheumatic drugs (DMARD) on different
events mediated by IL-15-activated lymphocytes.
Methods: Peripheral blood lymphocytes (PBL) were
isolated from healthy donors and activated with IL-15
after exposure to different DMARD: leflunomide, cyclo-
sporin A, methotrexate, mycophenolic acid, FK-506,
sulphasalazine and sodium aurothiomalate. The expres-
sion of different surface molecules on the PBL was then
determined by flow cytometry. Cells were also co-
cultured with the monocytic cell line THP-1 and the
tumour necrosis factor (TNF) concentration in the
supernatant was measured after 24 h using an immuno-
enzyme assay. The effect of the aforementioned drugs on
IL-17 production by IL-15-activated PBL was also studied.
Results: Treatment of PBL with leflunomide, cyclosporin
A and FK-506 inhibited the IL-15-induced expression of
both CD54 and CD69 by PBL, as well as TNF production in
co-cultures of activated PBL and THP-1 cells. The
downregulation of CD54 and CD69 in PBL was correlated
with the inhibition of TNF production. Likewise, lefluno-
mide, cyclosporin A and FK-506 all inhibited IL-17
production in IL-15-activated PBL. Interestingly, the effect
of leflunomide was not reverted by the presence of uridine
in the medium. In addition, leflunomide inhibited the
phosphorylation of STAT6 in vitro.
Conclusion: Inhibition of the JAK/STAT pathway may
represent an additional effect of leflunomide in chronic
polyarthritis because it impairs certain events that control
proinflammatory TNF and IL-17 cytokine production.
Research on the pathogenesis of rheumatoid
arthritis (RA) has led to the development of agents
that target specific regulators of key events in the
perpetuation of rheumatoid synovitis. Despite the
therapeutic impact of these new biological agents
in the rheumatology community, standard disease-
modifying antirheumatic drugs (DMARD) are still
successfully prescribed to many patients. In con-
trast to biological therapies, the identification of
DMARD effective in RA was serendipitous, and
the mechanisms through which many of these act
are not yet fully understood.
1 As it is now more
common to prescribe combined therapies to RA
patients, involving either different DMARD or the
combination of biological therapies and DMARD,
it is becoming more important to understand the
mode of action of these drugs.
One area of particular interest in RA research is
the proinflammatory loop that may be established
through the interactions between fibroblasts/
macrophages and activated lymphocytes.
2–7
Indeed, peripheral blood lymphocytes (PBL) acti-
vated with IL-15 can induce tumour necrosis factor
(TNF) production in macrophagic cells.
58 It is
notable that higher concentrations of IL-15 can be
found in the synovial fluid and serum from RA
patients than patients with other inflammatory
arthropathies.
5 9–11 Therefore, we have addressed
the effect of several DMARD on the IL-15-
mediated activation of PBL and on the induction
of TNF production by macrophages under these
conditions. Our results suggest that some DMARD
may exert their beneficial effect in RA patients by
inhibiting events induced by IL-15 in lymphocytes.
Furthermore, leflunomide appears to mediate this
effect by interfering with the JAK/STAT pathway.
MATERIAL AND METHODS
Antibodies and reagents
The anti-CD18 (Lia 3/2) and anti-CD69 (TP1/55)
monoclonal antibodies (mAb) have been described
previously.
12 The anti-CD54 (Hu5/3) mAb was
kindly provided by Dr Luscinskas (Harvard Medical
School, Boston, Massachusetts, USA). The
MAB002 IgG1 negative control was purchased
from R&D Systems (Minneapolis, MN) and the
anti-CD154 (24–31) mAb was from Alexis
Biochemicals (San Diego, California, USA).
Recombinant human IL-15 was supplied by
PeproTech EC (London, UK). Cyclosporin A,
mycophenolic acid, FK-506, methotrexate and the
specific inhibitor of JAK3, 4-(49-hydroxyphenyl)a-
mino-6,7-dimethoxyquinazoline were provided by
Calbiochem (La Jolla, California, USA).
Sulphasalazine, uridine and guanosine were pur-
chased from Sigma-Aldrich (Steinheim, Germany).
Sodium aurothiomalate (gold salts) was supplied
by Laboratorios Rubio (Madrid, Spain). The active
metabolite of leflunomide, A77-1726, was kindly
provided by Dr ML Herrmann (Aventis Pharma,
Frankfurt, Germany).
Cells, cell stimulation and DMARD treatment
PBL were isolated from venous blood samples from
healthy donors by Histopaque-1077 density-gradi-
ent centrifugation (Sigma Diagnostics, St Louis,
Missouri, USA). Monocytes were removed by
adhesion to Petri dishes (Costar, Cambridge,
Massachusetts, USA). The human monocytic
leukemia cell line THP-1 was maintained in
RPMI 1640 medium (Flow Laboratories, Irvine,
UK) supplemented with 10% fetal calf serum
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streptomycin (50 mg/ml; Bio Whitaker, Walkersville, Maryland,
USA).
PBL were incubated for 30 minutes in medium alone or with
the following DMARD: A77-1726 (3-100 mmol); cyclosporin A
(0.1–10 mg/ml); methotrexate (0.5–50 mg/ml); mycophenolic
acid (0.01–1 mmol); FK-506 (0.01–1 mg/ml); sulphasalazine
(100–1000 mg/ml) and gold salts (0.01–1 mg/ml). Subsequently,
PBL were activated with IL-15 (50 ng/ml) for 24 h in the
presence or absence of the DMARD. Cell viability after
treatment was assessed by propidium iodide (Sigma-Aldrich)
uptake (see supplementary table 1 available online only).
After 24 h of incubation with IL-15 and DMARD, PBL were
washed three times with 10 ml of RPMI 1640 without
supplementation with fetal calf serum or antibiotics. Then,
the cellular pellets were resuspended in complete RPMI to be co-
cultured with THP-1 cells at a final concentration of 10
6 PBL
and 10
5 THP-1 cells (10 : 1 ratio) by each millilitre of
medium.After co-culturing for 24 h, the supernatants were
harvested and stored at 230uC. In each assay, we included a
control in which the activated lymphocytes and monocytic cells
were separated by a 0.4 mm pore membrane in a transwell.
Flow cytometry
After treatments, PBL were incubated with mAb against CD18,
CD54, CD69, CD154 or a negative control mAb at 4uC for
30 minutes. Then, the cells were labelled with FITC goat anti-
mouse immunoglobulin (Dako, Salstrup, Denmark) at 4uC for
30 minutes. At least 5 610
3 cells were then analysed using a
FACScan flow cytometer (Becton Dickinson Biosciences, San
Jose, California, USA) and the data were collected using both a
logarithmic and a linear scale. Data were normalised and
expressed as the relative mean fluorescence intensity (rMFI) as
follows:
rMFI = [(MFIMolecule 2 MFINegative control)/(MFIMolecule IL-15 2
MFINegative control IL-15)] 6100
In some figures the data are shown as the percentage of the
inhibitory effect of DMARD:
Inhibition(%) = 100 2 [(MFIIL-15 + DMARD 2 MFIIL-15+medium) 6
100/(MFIIL-15+medium)]
Quantification of cytokine concentration
The TNF concentration in the supernatants was measured
using a sandwich enzyme immunoassay (EIA). The capturing
antibody was the anti-TNF MAB610 (R&D Systems Europe
Ltd, Abingdon, UK) used at a concentration of 8 mg/ml and the
detection antibody was biotinylated anti-TNF mAb, BAF210
(R&D Systems) used at 200 ng/ml. As TNF production varied
widely depending on the lymphocyte donor, in some figures it
was normalised to the percentage inhibition of TNF production
provoked by DMARD as follows:
Inhibition of TNF production = 100 2 [(TNFDMARD 2
TNFTw)/(TNFmedium 2 TNFTw)]
To measure IL-17 concentrations in supernatants of IL-15-
activated PBL the capturing antibody was the anti-IL17 mAb
MAB317 (R&D Systems) used at a concentration of 4 mg/ml
and the secondary antiserum was a biotinylated polyclonal anti-
IL-17, BAF317, used at 100 ng/ml (R&D Systems). As IL-17
production varied depending on the lymphocyte donor, it was
normalised considering 100% the IL-17 production of lympho-
cytes stimulated with IL-15 in the absence of DMARD:
IL-17 production = (IL-17DMARD*100)/IL-17medium)
In all cases cytokine values were calculated from the standard
curves and the samples that generated values higher than the
highest standard were diluted (1 : 1) in diluent buffer and
assayed again.
STAT6 Western blot analysis
PBL were incubated for 30 minutes in medium alone or in the
presence of A77-1726 at different concentrations (1–100 mmol),
and subsequently lymphocytes were activated with IL-15 (50
ng/ml) for 5 minutes. The cells were then lysed in Laemmli
buffer with 5% b-mercapto-ethanol, sonicated twice for 30 s at
4uC and boiled for 5 minutes at 100uC. All cell extracts were
separated on 10% sodium dodecylsulphate–polyacrylamide gel
electrophoresis gels and transferred to nitrocellulose membranes
(Bio-Rad Laboratories; Hercules, California, USA). The nitro-
cellulose was blocked in 5% non-fat dry milk in TBST (50 mmol
Tris base, 150 mmol NaCl, 0.1% Tween 20) for 15 minutes
followed by 5 minutes wash in TBST. The membranes were
then incubated overnight with an anti-human STAT6, phos-
pho-specific (Tyr
641) mAb diluted 1 : 1000 (clone 16E12;
Calbiochem), and after three washes with TBST, they were
exposed to a goat anti-mouse IgG horseradish peroxidase-
labelled antibody (Pierce Biotechnology; Rockford, Illinois,
USA) diluted 1 : 2000 in TBST for 45 minutes. After six washes
in TBST, the membranes were developed by chemiluminescence
with SuperSignal West Femto maximum sensitivity substrate
(Pierce Biotechnology) and analysed with Image Gauge 3.4
software (Fuji Photo Film, Tokyo, Japan). To reprobe the blot
and measure the loading control, the membranes were stripped
with Restore Western blot stripping buffer (Pierce
Biotechnology) at 42uC for 30 minutes. After blocking again,
the membranes were incubated with the anti-human tubulin
mAb DM1A (Sigma-Aldrich) at room temperature for 1 h,
washed and developed as described above. Band intensity was
determined by scanning the images with Image Gauge 3.4
software and the results were normalised considering the
STAT6 phosphorylation when PBL were activated by IL-15
without previous exposure to A77-1726 at 100%.
Statistics
The statistical analysis was performed using Stata 9.2 for
Windows. Variables with non-Gaussian distribution were
analysed using the Kruskall–Wallis test and each treatment
was compared with the data from the cells exposed to medium
alone using a Mann–Whitney test with Bonferroni correction.
Table 1 Inhibitory effect of A77-1726 and cyclosporin A on the
expression of CD54 and CD69 induced by IL-15 in PBL
CD69 p Value CD54 p Value
A77–1726
3 mmol 20.3 (5.6) 0.004 36.4 (11.5) 0.023
10 mmol 25.2 (8.3) 54.2 (22.1)
30 mmol 35.2 (8.4) 84.7 (34.6)
100 mmol 49.4 (9.1) 94.4 (33.5)
Cyclosporin A
0.1 mg/ml 28.9 (4.5) ,0.001 23.4 (6.8) 0.004
1 mg/ml 48.1 (15.9) 66.8 (36.67)
10 mg/ml 57.3 (13.7) 94.8 (47.4)
PBL, peripheral blood lymphocytes.
Data are shown as the mean (SEM) of the percentage of inhibition of IL-15-induced
expression exhibited by each molecule in (n = 8). The statistical significance of the
relationship between drug dose and each molecule expression was determined by
using linear regression. The multivariable analysis included the molecule expression as
dependent variable and drug dose and experiment (to adjust for variability in molecule
expression and individual response to treatment) as independent variables.
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Ann Rheum Dis 2009;68:1644–1650. doi:10.1136/ard.2008.096743 1645Figure 1 Effect of different disease-modifying antirheumatic drugs (DMARD) on the upregulation of CD69 induced by IL-15 in peripheral blood
lymphocytes (PBL) and on tumour necrosis factor (TNF) production by THP-1 cells induced by IL-15-activated PBL. PBL were exposed to A77-1726 (the
active metabolite of leflunomide; 100 mmol), cyclosporin A (10 mg/ml), methotrexate (50 mg/ml), mycophenolic acid (1 mmol), FK-506 (1 mg/ml),
sulphasalazine (1000 mg/ml) or sodium aurothiomalate (1 mg/ml) for 30 minutes. The cells were then stimulated with IL-15 (50 mg/ml) for 24 h and
afterwards they were used in different assays: (A) The expression of CD69 was assessed by flow cytometry. Data are shown as the median (top of
histogram) and interquartile range (IQR; the 25th and 75th percentiles being the lower and upper ends of the bar, respectively) of the relative mean
fluorescence intensity (rMFI) from 10 independent experiments. (B) The IL-15-stimulated PBL were washed and co-cultured with THP-1 cells for an
additional 24 h. In some experiments, the PBL and THP-1 cells were separated with a 0.4 mm pore transwell to define the effects that were independent
of cell–cell contact (Tw). TNF release was measured in cell-free supernatants by enzyme immunoassay. The data are shown as the median and IQR of
TNF production (pg/ml) from 15 independent experiments. The statistical significance in these multiple experiments (A and B panels) was determined
using the Kruskall–Wallis test, followed by comparison of each treatment with respect to the medium alone using a Mann–Whitney test with Bonferroni
correction (significance level considered if p,0.01). (C) Effect of the combination of cyclosporin A and A77-1726 on TNF production. Cells were treated
as described above, except in the combined condition in which the lymphocytes were incubated with cyclosporin A (0.1 mg/ml) and A77-1726
(3 mmol) for 10 minutes before IL-15 stimulation. The data are shown as the median and IQR of TNF production (pg/ml) from five independent
experiments. (D and E) Correlation between the inhibitory effects of DMARD on lymphocyte CD69 (D) and CD54 (E) expression and TNF production. The
data are the mean ¡ SEM of the percentage inhibition of CD69 or CD54 expression or TNF production, from eight independent experiments. Medium
represents cells stimulated with IL-15 in the absence of DMARD. Statistical analysis was performed by using Spearman correlation test. CyA,
cyclosporin A; GS, gold salts; MA, mycophenolic acid; MTX, methotrexate; SSZ, sulphasalazine.
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variance test. Accordingly, data were presented as median and
interquartile range when non-parametric tests were applied or
as mean (SEM) in normally distributed variables.
RESULTS
Effect of different DMARD on the IL-15-mediated upregulation of
CD69 and CD54 expression in peripheral blood lymphocytes
Different cell surface receptors, such as CD18, CD54, CD69 or
CD154 have been involved in the activating interactions
between lymphocytes and macrophages.
35 – 7 Whereas the
expression of CD69 and CD54 was induced by IL-15, CD18
and CD154 expression was not affected by this cytokine (data
not shown). Therefore, we tested the effect of different drugs
on the ability of IL-15 to upregulate CD69 and CD54 expression
in PBL.
The active metabolite of leflunomide, A77-1726, cyclosporin
A and FK-506 all inhibited the upregulation of CD69 and CD54
induced by IL-15 in PBL in a dose-dependent manner (fig 1A,
table 1). In contrast, methotrexate, sulphasalazine, mycophe-
nolic acid and gold salts did not exert any effect on the
expression of these molecules (fig 1A).
Effect of different DMARD on TNF production by macrophagic
cells induced by IL-15-activated PBL
We next assessed the effect of DMARD in a model of TNF
production when IL-15-activated PBL were co-cultured with
THP-1. When PBL were activated with IL-15 in the presence of
A77-1726, FK-506 or cyclosporin A, TNF production in the co-
cultures with THP-1 cells was inhibited by 38% (SEM 7), 56%
(SEM 16) and 52% (SEM 9), respectively (fig 1B). In contrast,
the incubation of PBL with methotrexate, sulphasalazine, gold
salts or mycophenolic acid did not induce any significant effect
on TNF production under these conditions (fig 1B). The effect
of A77-1726 and cyclosporin A was dose-dependent, and in
combination they inhibited TNF production to a similar extent
to that induced by each individual drug at a concentration 10-
fold higher (fig 1C).
We then studied whether the effect of DMARD on the
expression of CD69 and CD54 by IL-15-activated PBL was
correlated with the inhibitory effect on the production of TNF
in co-cultures of PBL and THP-1 cells. The inhibition of TNF
production by THP-1 cells was closely correlated with the level
of CD69 expression on IL-15-activated lymphocytes following
exposure to DMARD (r = 0.63, p,0.001; fig 1D). However,
the inhibition of CD54 expression by DMARD was more
weakly correlated with the inhibition of TNF production
(r = 0.42, p=0.009; fig 1E).
Effect of different DMARD on the production of IL-17 induced by
IL-15 in PBL
It has been shown that IL-15 triggers IL-17 production ‘‘in
vitro’’ through a cyclosporin A-sensitive mechanism.
13 We thus
tested whether the aforementioned DMARD affected the IL-15-
mediated production of IL-17 by PBL. The synthesis of IL-17
was time dependent and it was optimal after 72 h of IL-15
stimulation (data not shown). Therefore, we first treated PBL
with DMARD and then stimulated them with IL-15 (50 ng/ml)
for 72 h. The treatment of PBL with A77-1726, FK-506 and
cyclosporin A significantly decreased IL-17 production (fig 2A)
and, surprisingly, mycophenolic acid also provoked a significant
inhibition of IL-17 synthesis (fig 2A). As this assay required 72 h
of culture ‘‘in vitro’’ and mycophenolic acid and A77-1726 block
guanosine and uridine synthesis, respectively, we assessed the
effect of supplementing the culture medium with either
guanosine (100 mmol) or uridine (100 mmol). While in the
presence of guanosine the effect of mycophenolic acid on IL-17
production was completely reverted, the presence of uridine
Figure 2 The effect of disease-modifying antirheumatic drugs
(DMARD) on IL-17 production induced by IL-15 in peripheral blood
lymphocytes (PBL). (A) PBL were pre-treated with A77-1726
(100 mmol), cyclosporin A (10 mg/ml), methotrexate (50 mg/ml),
mycophenolic acid (MA); 1 mmol), FK-506 (1 mg/ml), sulphasalazine
(1000 mg/ml) and sodium aurothiomalate (1 mg/ml) for 30 minutes and
then stimulated with IL-15 (50 mg/ml) for 72 h. The supernatants were
then harvested and IL-17 release was measured in cell-free supernatants
by enzyme immunoassay (EIA). Data are shown as the median (top of
histogram) and interquartile range (IQR; the 25th and 75th percentiles
being the lower and upper ends of the bar, respectively) of the
percentage of IL-17 production from 11 independent experiments. IL-17
production in the condition without DMARD treatment was considered
100% and it corresponds to a median concentration of IL-17 of 216 pg/ml
(IQR 144–233). The statistical significance (*) in these multiple condition
experiments was determined using the Kruskall–Wallis test followed by
comparison of each treatment with the results obtained with medium
alone using the Mann–Whitney test with Bonferroni correction
(significance level p,0.01). (B) PBL were pre-treated with A77-1726
(30 mmol) in the presence or absence of uridine (100 mmol), as well as
with mycophenolic acid (1 mmol) in the presence or absence of
guanosine (100 mmol) for 30 minutes and they were then stimulated
with IL-15 (50 mg/ml) for 72 h. The supernatants were harvested and IL-
17 release was measured in cell-free supernatants by EIA. The data are
shown as the median and IQR of the percentage of IL-17 production from
six independent experiments. IL-17 production in the condition without
DMARD treatment was considered 100% and it corresponds to a median
concentration of IL-17 of 382 pg/ml (IQR 249–624).
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the production of IL-17 induced by IL-15 (fig 2B).
Leflunomide inhibits the phosphorylation of STAT6
In light of the results presented above, we also tested the effect
of A77-1726 upon CD69 and CD54 expression in the presence of
uridine (100 mmol). Under these conditions, uridine did not
prevent either the inhibitory effect of A77-1726 (30 mmol) on
the upregulation of CD69 induced by IL-15 (fig 3A, left and
middle panels), or the effect of A77-1726 on the IL-15-induced
expression of CD54 (data not shown).
It has been suggested that A77-1726 can interfere with signal
transduction, probably by inhibiting tyrosine kinases.
14 In this
regard, JAK3 is known to be involved in the signalling of the
IL-15 receptor.
15 Interestingly, a specific inhibitor of JAK3
produced a similar effect to that of A77-1726 on IL-15-induced
CD69 expression in PBL (fig 3A, right panel), raising the
possibility that leflunomide inhibits IL-15 signalling. We there-
fore studied the ability of this drug to inhibit STAT6
phosphorylation in PBL after IL-15 stimulation, and indeed
A77-1726 caused a dose-dependent inhibition of STAT6
phosphorylation at doses similar to those used above (fig 3B
and C). Similar results were obtained when we studied STAT3
phosphorylation (data not shown).
DISCUSSION
Cell–cell interactions significantly contribute to synovial inflam-
mation in RA.
16 In the model of TNF production in co-cultures of
IL-15-activated lymphocytes and monocytic THP-1 cells, our data
confirm the relevance of CD54 and CD69 previously estab-
lished.
35Therefore, we show that the DMARD that are able to
inhibit the IL-15-mediated upregulation of CD54 and CD69
interfere with TNF production in this model. The data regarding
CD69 are of particular interest because the elusive nature of its
ligand has prevented its role in autoimmune disorders from being
mechanistically characterised. Our data show a clear dose-
dependent relationship between the expression of CD69 on
lymphocytes and the production of TNF by macrophagic cells,
suggesting that CD69 upregulation in lymphocytes could be more
relevant than that of CD54 in this model.
Figure 3 The inhibitory effect of A77-
1726 on lymphocyte CD69 upregulation
induced by IL-15 is mediated through the
JAK/STAT pathway. (A) Peripheral blood
lymphocytes (PBL) were treated with
A77-1726 (30 mmol) for 30 minutes and
then stimulated with IL-15 (50 mg/ml) for
24 h, in the absence (left panel) or
presence (middle panel) of uridine
(100 mmol). The effect of the JAK-3
inhibitor, 4-(49-hydroxyphenyl)amino-6,7-
dimethoxyquinazoline (10 mg/ml), is
represented in the right panel. One
representative experiment of four is
shown and, in each panel, the following
histograms are represented: negative
control (dotted line), CD69 basal
expression (green solid line), CD69
expression after IL-15 stimulation (black
solid line), CD69 expression in PBL
treated with A77-1726 or JAK-3 inhibitor
and stimulated with IL-15 (red solid line).
(B) PBL were pretreated with A77-1726
at different doses (1, 3, 10, 30 and
100 mmol) or with medium alone for
30 minutes, and they were then
stimulated with IL-15 (50 ng/ml) for
5 minutes. The cells were lysed and the
lysates processed to detect the
phosphorylated form of STAT6 (upper
line) or tubulin (lower line) as described in
the Materials and methods section. The
figure represents one of five independent
experiments. (C) Band intensities were
quantified from the nitrocellulose
membranes using Image Gauge 3.4
software. Values were normalised
considering 100% the intensity of the
band obtained with lysates from PBL
stimulated with IL-15 in absence of
leflunomide pretreatment. Data are shown
as the mean ¡ SEM of five independent
experiments and the statistical
significance was determined with an
analysis of variance with the Bonferroni
correction.
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inhibit key events in the perpetuation of TNF and IL-17
production may further explain the effectiveness of these
compounds in the treatment of RA. Indeed, IL-17 acts
synergistically with TNF and IL-1 to induce RANKL synthesis
and therefore mediates metalloprotease synthesis by synovio-
cytes and osteoclast formation.
17 The inhibition of both TNF
and IL-17 production when lymphocytes are exposed to
cyclosporin A and leflunomide could thus explain the preven-
tion of radiological progression in RA patients undergoing
treatment with these drugs.
18 19
Regarding the mechanism by which cyclosporin A, FK-506
and leflunomide influence the IL-15-mediated synthesis of
CD69 and IL-17, cyclosporin A-sensitive sequences have been
identified in the promoter of CD69,
20 and IL-17 production
induced by IL-15 was previously reported to be inhibited by
cyclosporin A.
13 It is conceivable that FK-506 exerts its
inhibitory effect in a similar way because both cyclosporin A
and FK-506 inhibit calmodulin and FK-506 has been shown to
inhibit the upregulation of CD69.
21 22 The mechanism by which
leflunomide acts is thought to involve the inhibition of ‘‘de
novo’’ pyrimidine nucleotide biosynthesis. However, we found
that uridine could not overcome the inhibition of IL-15-
mediated events. IL-15 receptor signalling involves, in part,
JAK1 and JAK3 kinases, which mediate the phosphorylation of
STAT3, STAT5 and STAT6.
15 Indeed, leflunomide can inhibit
tyrosine kinases and especially JAK3 kinase.
23 24 Interestingly,
we found that a specific inhibitor of JAK3 inhibits both the
upregulation of CD69 and the synthesis of IL-17 induced in PBL
by IL-15 to a similar extent as A77-1726 (the active metabolite
of leflunomide). Moreover, we have demonstrated that A77-
1726 inhibited the phosphorylation of STAT6 and STAT3
induced by IL-15.
However, A77-1726 is a more potent inhibitor of dihydro-
orotate dehydrogenase than of JAK3 kinase in murine models.
23
Whether this also occurs in humans was not clear. Here, we
demonstrated the inhibition of STAT6 phosphorylation in
human PBL at low A77-1726 concentrations, similar to those
detected in the serum of patients treated with leflunomide.
25 A
toxic effect can also be ruled out because other authors have
shown that lymphocytes exposed to A77-1726 at 100 mmol are
viable and they upregulate their CD69 expression when they are
exposed to phytohaemagglutinin plus phorbol myristate acet-
ate.
26 In addition, it has also been described that leflunomide can
induce other anti-inflammatory events that can not be
explained by the inhibition of dihydroorotate dehydrogen-
ase.
27 28 All these findings suggest that inhibition of tyrosine
kinases may contribute to the antirheumatic effects of
leflunomide.
With respect to the clinical application of these findings,
combined therapies seem to offer strategies to improve disease
activity, disability and to prevent radiological progression.
29–31
Here, we provide information regarding the effect of cyclosporin
A and leflunomide on lymphocyte-mediated mechanisms
involved in the perpetuation of synovial inflammation.
Conversely, other DMARD such as methotrexate or sulphasa-
lazine have been shown directly to inhibit monocytic cells and
synoviocytes.
32 33 Therefore, to combine DMARD with different
mechanisms of action, in order to interact with a wider range of
pathogenic pathways involved in chronic synovitis, should
result in a better control of inflammation.
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